Evaluating Darbepoetin Treatment Strategies for Managing Anaemia in Haemodialysis Patients: Effects on All‐Cause Mortality From a Target Trial Emulation Using Electronic Health Record Data
Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)
DOI: 10.1002/pds.70507 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 18.10.2026. Verfasst von Kate Birnie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Darbepoetin alfa, Anemia, Renal Dialysis, Hematinics. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Institute for Health Research Applied Research Collaboration West, NIHR Bristol Biomedical Research Centre.
Abstract (Originalsprache)
Purpose
Anaemia is a common complication of chronic kidney disease, often treated with erythropoiesis‐stimulating agents (ESAs), but the optimal haemoglobin (Hb) target remains uncertain. Using electronic health records, we emulated a target trial comparing different Hb targets in haemodialysis patients to estimate their effects on mortality.
Methods
We used electronic health records from UK kidney centres reporting to the UK Renal Registry. Adults aged ≥ 18 years, receiving haemodialysis for ≥ 3 months, and without marked ESA resistance were eligible. Using the clone‐censor‐weight method, we emulated trials comparing Hb targets: (1) 105–125 versus 95–115 g/L and (2) 125–145 versus 95–115 g/L. Darbepoetin dosing followed a standardised protocol with predefined dose adjustments and a maximum dose of 150 μg/week. The outcome was all‐cause mortality over 8 months.
Results
The study included 8628 patients from 10 centres between 2004 and 2016; 62% male, median age 66 years (IQR 52–76). At baseline, mean Hb was 97.7 g/L (SD 15.1), and 79% of patients were receiving darbepoetin. The hazard ratio for mortality was 0.92 (95% CI 0.75–1.12) for the 105–125 versus 95–115 g/L comparison, and 1.20 (95% CI 0.94–1.54) for the 125–145 versus 95–115 g/L comparison. Adherence to the highest Hb target was lower, limiting precision.
Conclusions
Targeting an Hb range of 105–125 g/L under controlled ESA dosing was not associated with increased mortality compared with 95–115 g/L. Targeting Hb levels above 125 g/L may increase mortality risk, consistent with previous trial findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- Renal Unit, Southmead Hospital, Bristol, UK.
- The National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
- Department of Noncommunicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
- Department of Nephrology, Royal Free London NHS Foundation Trust, London, UK.
- UK Renal Registry, Bristol, UK.
ORCID-Profile: Kate Birnie, Yoav Ben-Shlomo, Dorothea Nitsch, Eleanor J Murray
Förderung
- Medical Research Council
- National Institute for Health Research Applied Research Collaboration West
- NIHR Bristol Biomedical Research Centre
Zitieren
APA
Birnie, K., Caskey, F. J., Ben-Shlomo, Y., Nitsch, D., Casula, A., Murray, E. J., & Sterne, J. A. C. (2026). Evaluating Darbepoetin Treatment Strategies for Managing Anaemia in Haemodialysis Patients: Effects on All‐Cause Mortality From a Target Trial Emulation Using Electronic Health Record Data. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70507
Vancouver
Birnie K, Caskey FJ, Ben-Shlomo Y, Nitsch D, Casula A, Murray EJ, et al. Evaluating Darbepoetin Treatment Strategies for Managing Anaemia in Haemodialysis Patients: Effects on All‐Cause Mortality From a Target Trial Emulation Using Electronic Health Record Data. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70507
BibTeX
@article{Birnie2026,
author = {Birnie, Kate and Caskey, Fergus J and Ben-Shlomo, Yoav and Nitsch, Dorothea and Casula, Anna and Murray, Eleanor J and Sterne, Jonathan A C},
title = {Evaluating Darbepoetin Treatment Strategies for Managing Anaemia in Haemodialysis Patients: Effects on All‐Cause Mortality From a Target Trial Emulation Using Electronic Health Record Data},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {11},
doi = {10.1002/pds.70507}
}
EUVIMED